Clinical Trial Update: Zyprexa and Task Engagement in Schizophrenia [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Zyprexa (olanzapine) for task engagement in schizophrenia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Zyprexa (olanzapine)

Snippet

Sponsor: VA Connecticut Healthcare System | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: WITHDRAWN